Get started
Author

Jeanne Yue

OpenAlex ID: A5042525406
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
2020 · M.C. Liu, G.R. Oxnard, et al. · Annals of Oncology · 1,483
PDF
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
2019 · Pedram Razavi, Bob T. Li, et al. · Nature Medicine · 774
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
2015 · Andrew M. Evens, Sriram Balasubramanian, et al. · Clinical Cancer Research · 96
A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
2012 · Andrew M. Evens, Julie M Vose, et al. · Blood · 25
Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
2018 · Alexander A. Aravanis, Geoffrey R. Oxnard, et al. · Cancer Research · 2
SUPPLEMENTARY DATA from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
2023 · Andrew M. Evens, Sriram Balasubramanian, et al.
SUPPLEMENTARY DATA from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
2023 · Andrew M. Evens, Sriram Balasubramanian, et al.
PDF
Data from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
2023 · Andrew M. Evens, Sriram Balasubramanian, et al.
Data from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
2023 · Andrew M. Evens, Sriram Balasubramanian, et al.
Works count: 9
Citation count: 2,380
H-index: 4
I10-index: 4
Year
Topic
Type